Ashley Dombkowski, Ph.D. is the CEO of BEFORE Brands, a consumer-focused product platform focused on health and wellness for parents and families. She co-founded the company in 2015 with Dr. Kari Nadeau, the Director of the Sean N. Parker Center for Allergy and Asthma research at Stanford University. She has 20 years of experience as an operating executive, entrepreneur, and investor in fields spanning the consumer health and life sciences fields. Her portfolio of innovative biotechnology, medical device, consumer health and HCIT companies has included 23andMe, Adolor, Alnara, BioVitrum, Epizyme, iPierian, Neosil, Nevro, Rigel, Tercica, and Twist. She previously served as a Managing Director with Bay City Capital, a $1.6B venture capital firm. Prior to that she served as Chief Business Officer and Vice President of Operations for 23andMe, where she oversaw the company’s finance and operations activities and had responsibility for the company’s long term business strategy. Before to joining 23andMe, she was a Managing Director with MPM Capital where she served as a member of the firm’s Investment Committee. Prior to this, she was an Equity Analyst for hedge fund Tiger Management L.L.C. and for institutional asset management firm Dresdner RCM Global Investors. Dr. Dombkowski holds a Ph.D. in Mathematics from Rice University and received her B.A. in Mathematics from Wellesley College. She has been widely quoted in publications ranging from Nature to The Wall Street Journal and she has appeared in media outlets including CNBC, SXSW, and TedMed. She was recognized as one of the 100 Most Influential Women in Business by the San Jose/Silicon Valley Business Journal in 2010. She is a member of the Board of Directors of USA Volleyball, the National Governing Body for all disciplines of Volleyball as recognized by the U.S. Olympic Committee, and serves as Chair of the Audit, Finance, and Budget committee.